venture fund, Lilly and Andreessen Horowitz

Spurred by AI’s possibilities, Eli Lilly and Andreessen Horowitz partner on $500M venture fund
Eli Lilly is partnering with the fabled venture capital firm Andreessen Horowitz on a new fund backed with $500 million of the drug giant’s money.
Eli Lilly, Andreessen Horowitz link up on $500M biotech venture fund
Eli Lilly and venture capital firm Andreessen Horowitz (a16z) are joining forces to create a unique new fund dubbed the Biotech Ecosystem Venture Fund, backed by $500 million of Lilly’s capital.
Lilly Partners With a16z on $500M VC Fund for Early-Stage Biotechs
The Biotech Ecosystem Venture Fund will combine the sourcing capabilities of venture capital firm Andreessen Horowitz (a16z) with Eli Lilly’s expertise in R&D—plus half a billion in capital from the Big Pharma.
Andreessen Horowitz, Eli Lilly to launch $500 million venture fund
Venture capital firm Andreessen Horowitz said on Friday it was working with Eli Lilly to launch a $500 million venture fund that will be fully funded by the U.S. drugmaker. WHY IT'S IMPORTANT The fund,
Andreessen Horowitz Partners with Lilly to Launch First-of-Its-Kind Biotech Ecosystem Venture Fund
Bio + Health today announced a newly formed, first-of-its-kind venture capital fund to fuel broader innovation in human health, in partnership with Eli Lilly and Company ("Lilly"). The Biotech Ecosystem Venture Fund ("Fund") seeks to drive transformative progress in healthcare by investing in therapeutic platforms and cutting-edge technology companies that can bring new medicines and disease treatments to improve patients' lives.
Pharmaceutical Technology17m
Mediar Therapeutics signs licensing deal with Eli Lilly for IPF treatment
Mediar has entered into a global licensing agreement with Eli Lilly to progress MTX-463 into a Phase II trial for the ...
Eli Lilly: Still Much Room To Ride The Weight-Loss Wave
Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a ...
Lilly in advanced talks to buy cancer biotech Scorpion for up to $2.5B, FT says
Eli Lilly (LLY) is in advanced talks to buy cancer-focused biotech Scorpion Therapeutics in a deal worth up to $2.5B, people close to the talks ...
BioSpace2d
Lilly Makes $780M+ IPF Play with Mediar Partnership
Eli Lilly’s idiopathic pulmonary fibrosis deal with Mediar is centered around MTX-463, an anti-WISP1 antibody that early ...
FiercePharma2d
Lilly doubles down on its presence in India with new capability center, plans to hire 1,000-plus
Eli Lilly has been operating a global capability center (GCC) in Bengaluru, India. | For nearly a decade, Eli Lilly has been ...
Eli Lilly's obesity drug gets Medicare coverage for sleep apnea
Eli Lilly's obesity drug Zepbound can now be covered by government-backed Medicare insurance plans for use in sleep apnea, ...
Exclusive: Arianna Huffington’s Thrive Global inks novel partnership with pharma giant Eli Lilly
Good morning! Meta's elimination of fact-checking opens the door to misogynistic speech, Jane Fraser faces a test at Citi, ...
Lilly Pulitzer Just Marked Down Some Of Our Favorite Styles By Up To 70%, But Only For 3 Days
Though we’re well into the winter season, Lilly Pulitzer always finds a way to get us excited for spring and summer. The ...
Kentucky’s cutest dog is a corgi with a mischievous streak. Meet Lilly, our poll winner
Forty submissions, weeks of polls and several thousand votes from Herald-Leader subscribers have finally brought us to this ...
Flynn: Eli Lilly could capture a significant part of a $100 billion market with Zepbound.
Terence Flynn, Biotech Analyst at Morgan Stanley, discusses Eli Lilly's recent stock boost and its designation as Morgan ...